investors.dandrit.com

DanDrit Biotech USA, Inc.—Investor Relations

DanDrit Biotech USA, Inc. Quarterly report [Sections 13 or 15(d)]. Acc-no: 0001213900-15-003597 (34 Act) Size: 3 MB. Current report, item 5.02. Acc-no: 0001615774-15-000993 (34 Act) Size: 14 KB. Current report, item 5.02. Acc-no: 0001615774-15-000864 (34 Act) Size: 18 KB. Annual report [Section 13 and 15(d), not S-K Item 405]. Acc-no: 0001213900-15-002253 (34 Act) Size: 6 MB. Current report, items 1.01, 5.02, and 9.01. Acc-no: 0001213900-15-001869 (34 Act) Size: 85 KB. Current report, items 1.01, 8&#...

http://investors.dandrit.com/

OVERVIEW OF investors.dandrit.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

2

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTORS.DANDRIT.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.0 out of 5 with 2 reviews

5 star

1

4 star

0

3 star

0

2 star

0

1 star

1

Hey there! Start your review of investors.dandrit.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

6.5 seconds

CONTACTS AT INVESTORS.DANDRIT.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

2

SSL

EXTERNAL LINKS

4

SITE IP

213.174.77.98

LOAD TIME

6.506 sec

SCORE

6.2

PAGE TITLE

DanDrit Biotech USA, Inc.—Investor Relations | investors.dandrit.com Reviews

<META> DESCRIPTION

DanDrit Biotech USA, Inc. Quarterly report [Sections 13 or 15(d)]. Acc-no: 0001213900-15-003597 (34 Act) Size: 3 MB. Current report, item 5.02. Acc-no: 0001615774-15-000993 (34 Act) Size: 14 KB. Current report, item 5.02. Acc-no: 0001615774-15-000864 (34 Act) Size: 18 KB. Annual report [Section 13 and 15(d), not S-K Item 405]. Acc-no: 0001213900-15-002253 (34 Act) Size: 6 MB. Current report, items 1.01, 5.02, and 9.01. Acc-no: 0001213900-15-001869 (34 Act) Size: 85 KB. Current report, items 1.01, 8&#...

<META> KEYWORDS

1 toggle navigation

2 about dandrit

3 research

4 investors

5 patients

6 type

7 interactive

8 files

9 filing date

10 data

CONTENT

Page content here

KEYWORDS ON PAGE

toggle navigation,about dandrit,research,investors,patients,type,interactive,files,filing date,data,html,docx,xlsx,xbrl,prospectus rule 424 b 3,prospectus rule 424 b 4,effect,notice of effectiveness,amend,cover,upload,sec generated letter

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

DanDrit Biotech USA, Inc.—Investor Relations | investors.dandrit.com Reviews

https://investors.dandrit.com

DanDrit Biotech USA, Inc. Quarterly report [Sections 13 or 15(d)]. Acc-no: 0001213900-15-003597 (34 Act) Size: 3 MB. Current report, item 5.02. Acc-no: 0001615774-15-000993 (34 Act) Size: 14 KB. Current report, item 5.02. Acc-no: 0001615774-15-000864 (34 Act) Size: 18 KB. Annual report [Section 13 and 15(d), not S-K Item 405]. Acc-no: 0001213900-15-002253 (34 Act) Size: 6 MB. Current report, items 1.01, 5.02, and 9.01. Acc-no: 0001213900-15-001869 (34 Act) Size: 85 KB. Current report, items 1.01, 8&#...

INTERNAL PAGES

investors.dandrit.com

1

View Filing Data

http://investors.dandrit.com/files/2015-05-13-10-q

DanDrit Biotech USA, Inc. (Filer). Document and Entity Information. Consolidated Balance Sheets (Parenthetical). Consolidated Statement of Operations (Unaudited). Statements of Other Comprehensive Loss (Unaudited). Consolidated Statement of Cash Flows (Unaudited). Notes to Financial Statements. Summary of Significant Accounting Policies. Definite Life Intangible Assets. Notes Payable - Related Party. Summary of Significant Accounting Policies (Policies). Property and Equipment (Tables). Mar 31, 2015.

2

View Filing Data

http://investors.dandrit.com/files/2015-03-31-10-k

DanDrit Biotech USA, Inc. (Filer). Document and Entity Information. Consolidated Balance Sheet (Parenthetical). Consolidated Statement of Operations. Consolidated Statements of Other Comprehensive Loss. Consolidated Statement of Stockholders' (Deficit). Consolidated Statement of Stockholders' (Deficit) (Parenthetical). Consolidated Statement of Cash Flows. Notes to Financial Statements. Summary of Significant Accounting Policies. Definite Life Intangible Assets. Notes Payable - Related Party. Dec 31, 2014.

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL PAGES IN THIS WEBSITE

2

LINKS TO THIS WEBSITE

dandrit.com

Disclaimer

http://www.dandrit.com/disclaimer

Any links to other Internet sites are provided as a convenience. DanDrit Biotech USA, Inc. has no responsibility nor control over the content or operation of such sites, and shall not be liable for any damages or injuries arising from that content or its operation. DanDrit Biotech USA, Inc. reserves its right to alter, modify, substitute or delete any content of or may restrict access to or discontinue distribution of this site at any time and at its sole discretion.

dandrit.com

Company Profile

http://www.dandrit.com/about/company-profile

DanDrit Biotech USA, Inc. is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. DanDrit Biotech A/S was founded in 2001 on the research of Professor Jesper Zeuthen at the Danish Cancer Society. The proprietary technology upon which MCV is based is protected by several issued patents. MelCancerVac (MCV) is a new product by DanDrit for colorectal cancer.

dandrit.com

“How Do I Get MelCancerVac®?”

http://www.dandrit.com/patients/getting-melcancervac

Ldquo;How Do I Get MelCancerVac? How Do I Get MelCancerVac? In order to be released to the general consumer and comply with regulations, medical drugs must undergo years upon years of testing and clinical trials. Due to a collaboration between DanDrit Biotech USA, Inc. and myTomorrows. Patients with colorectal cancer can obtain DanDrit’s MelCancerVac. Even as the drug continues to undergo clinical trials and has yet to be released on the consumer market. MyTomorrows provide so-called Fast Track Treatments.

dandrit.com

MelCancerVac®

http://www.dandrit.com/products/melcancervac

MelCancerVac Polyvalent Vaccine Targeting Shared Tumor-Specific Antigens. This page is an excerpt from the Research section Vaccine Platform. The main product of DanDrit Biotech USA, Inc. is MelCancerVac , which uses a patient’s own dendritic cells loaded with tumor antigens from the lysate of a specifically selected melanoma cell line. For information on obtaining the product, see the section How Do I Get MelCancerVac? MelCancerVac (MCV) is a new product by DanDrit for colorectal cancer.

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL LINKS TO THIS WEBSITE

4

OTHER SITES

investors.ctrinvestors.com

User Login

investors.cubesmart.com

Investor Relations, Corporate Profile | CubeSmart, U•Store•It Reinvented

Choose your storage type:. Report of Organizational Actions - IRS form 8937. CUBESMART (NYSE - CUBE). Friday, August 07, 2015. CubeSmart Second Quarter 2015 Earnings Call. Our strategy is to grow our property portfolio by being a consolidator in the highly fragmented self-storage industry. We believe these acquisitions will offer the Company economies of scale by spreading our management expertise and operating efficiency across a larger portfolio. We look to maximize the cash flow from our facil...As of...

investors.curis.com

Investor Relations - Curis - Investor Relations

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. The Company currently has two drug candidates in development:. CUDC-907, an orally available small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors. Mar 8, 2018. Mar 5, 2018. Curis,...

investors.cynosure.com

Investor Home | Investors | Cynosure

Your Practice and Cynosure. Q2 2015 Cynosure Inc. Earnings Conference Call. 160;at 9:00 am ET. Q2 2015 Cynosure Inc. Earnings Conference Call. Tuesday, July 28, 2015 . 9:00 am ET . Click here for webcast. 160; 0.62. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. July 28, 2015. Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year. July 14, 2015. Cynosure to Host Second-Quarter 2015 Financial Results Conference Call on July 28.

investors.cypress.com

Investor Relations - Cypress Semiconductor Corporation

Body and Comfort Electronics. 80211n Wi-Fi with MCU. Bluetooth Low Energy (BLE). PSoC 6 32-bit IoT MCUs. Traveo 32-bit ARM Auto MCUs. PSoC 32-bit ARM Cortex MCUs. 16-bit and 8-bit MCUs. Universal Serial Bus (USB). USB Type-C and Power Delivery. LED Lighting Driver ICs. Serial (QSPI) NOR Flash. Create a Support Case. Report a Website Problem. Bluetooth Low Energy (BLE). Universal Serial Bus (USB). Environmental Health and Safety. 10 being Extremely likely, 5 being neutral and 0 being not likely at all.

investors.dandrit.com

DanDrit Biotech USA, Inc.—Investor Relations

DanDrit Biotech USA, Inc. Quarterly report [Sections 13 or 15(d)]. Acc-no: 0001213900-15-003597 (34 Act) Size: 3 MB. Current report, item 5.02. Acc-no: 0001615774-15-000993 (34 Act) Size: 14 KB. Current report, item 5.02. Acc-no: 0001615774-15-000864 (34 Act) Size: 18 KB. Annual report [Section 13 and 15(d), not S-K Item 405]. Acc-no: 0001213900-15-002253 (34 Act) Size: 6 MB. Current report, items 1.01, 5.02, and 9.01. Acc-no: 0001213900-15-001869 (34 Act) Size: 85 KB. Current report, items 1.01, 8&#...

investors.dctindustrial.com

Corporate Profile | DCT

Active in the Market. SEC Filings and Financial Documents. Tax Treatment of Dividends. DRIP Dividend Reinvestment Plan. Email / Mobile Notifications. REITWeek: NAREIT’s Investor Forum for 2015. Wednesday June 10, 2015 at 10:15 AM ET. REITWeek: NAREIT’s Investor Forum for 2015. Click here to view the archived webcast. DCT Industrial Second Quarter 2015 Earnings Call. Friday July 31, 2015 at 11:00 AM ET. Click here to download Adobe Acrobat Reader. As of August 7, 2015. Minimum 20 minute delay. College Sta...

investors.de

Willkommen bei Investors Management in Stuttgart

BGV / Badische Allgemeine. Vita - Armin Sturm. Ihr Weg zu uns. Intelligente Lösungen für Makler und Vertriebsgesellschaften - Wir begleiten Sie vom Angebot bis zur Vertragsverwaltung. Intelligente Lösungen für Makler und Vertriebsgesellschaften. Der Service für Makler ist unsere erste Pflicht. Die Vielzahl der Anbieter im Bereich. Finanzdienstleistungen, geht weit über unsere Vorstellungskraft hinaus. Somit ist es für einen einzelnen Makler nur mit sehr hohem Aufwand möglich,. News aus dem Markt:.

investors.deltagas.com

Delta Natural Gas Company, Inc. - Investor Relations - Investor Overview

3617 Lexington Rd. Winchester, KY 40391. Customer Service Contact Numbers. What To Do If You Smell Gas. Safety Data Sheet Info. Call Before You Dig. Recognizing and Reporting Emergencies. What is Customer Piping? Call Before You Clear Your Sewer Line! Stock Quote and Chart. Annual Reports and Proxy. Customer Service Contact Numbers. What To Do If You Smell Gas. Safety Data Sheet Info. Call Before You Dig. Recognizing and Reporting Emergencies. What is Customer Piping? Stock Quote and Chart. DELTA’S THREE...

investors.demandware.com

Investor Relations

Demandware’s press room offers a single view of information, from the latest news releases and media coverage to downloads on important topics. Read our latest financial results:. Q2 Earnings Press Release. Learn more about our value proposition:. Access the audio webcast from our earnings call and our quarterly report:. Most Recent Quarterly Information. Demandware Announces Second Quarter 2015 Financial Results. Demandware Sets Date to Announce Second Quarter 2015 Financial Results. Brentwood, NY 11717.

investors.dentsplysirona.com

Dentsply Sirona - Investors - Investors

Press Releases and News. Welcome to Dentsply Sirona's Investor Relations web site. Whether you're a Dentsply Sirona investor or potential investor - or simply want to learn more about our Company - we hope you'll find the information here useful and interesting. Press Releases and News. Financial Information and Quarterly Results. Data as of 01/11/17 4:15 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. VP, Investor Relations. VP, Investor Relations and Corporate Communications.